Insider Selling: Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells 10,457 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) General Counsel David Aaron Lehman sold 10,457 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total transaction of $32,730.41. Following the sale, the general counsel now owns 273,039 shares of the company's stock, valued at $854,612.07. This represents a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulmonx Stock Down 3.1%

Shares of Pulmonx stock traded down $0.10 during trading on Wednesday, hitting $3.08. The company's stock had a trading volume of 249,343 shares, compared to its average volume of 312,447. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company has a fifty day simple moving average of $4.49 and a two-hundred day simple moving average of $6.01. The company has a market capitalization of $123.99 million, a PE ratio of -2.14 and a beta of 0.52. Pulmonx Co. has a 52 week low of $2.83 and a 52 week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $22.54 million for the quarter, compared to the consensus estimate of $22.03 million. Equities research analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Citigroup decreased their price objective on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Jefferies Financial Group assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a "buy" rating for the company. Canaccord Genuity Group decreased their price objective on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Piper Sandler restated an "overweight" rating and issued a $9.00 price objective (down from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Finally, Morgan Stanley assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an "equal weight" rating for the company. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Pulmonx has an average rating of "Moderate Buy" and a consensus price target of $11.59.

Institutional Trading of Pulmonx

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new stake in shares of Pulmonx during the 4th quarter valued at about $43,000. ProShare Advisors LLC purchased a new position in shares of Pulmonx in the fourth quarter worth approximately $72,000. Stifel Financial Corp purchased a new position in shares of Pulmonx in the fourth quarter worth approximately $81,000. Vontobel Holding Ltd. purchased a new position in shares of Pulmonx in the first quarter worth approximately $82,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Pulmonx by 27.0% in the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after buying an additional 3,310 shares during the last quarter. Hedge funds and other institutional investors own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.